Join us as we confront the open challenges of applying GenAI in drug discovery pipelines: meeting project goals under strict design constraints and synthetic feasibility.
In this webinar, we’ll explore how Iktos rethinks GenAI through a chemistry-driven lens—empowering medicinal chemists to take control of generative design with multi-parametric reward functions and real-time synthesis awareness. Learn how to elevate virtual experimentation by prioritizing only synthesizable, low-risk, high-potential hits.
Agenda Highlights
- The unsolved problems of GenAI in Pharma
- How to rethink generative design with chemistry-first logic
- Running virtual experiments using chemistry-driven reward functions
- The real-world impact of this approach in discovery programs
Whether you're a chemist or a decision-maker in discovery, this session will help you unlock the potential of GenAI under real chemistry constraints.
Webinar registration
US - Europe time: Session #01 June 18th 2025, 5 pm CET - 11 am EST
Europe - Asia time: Session #02 June 19th 2025, 9 am CET - 4 pm JST
Speakers
Quentin Perron
Chief Scientific Officier & Co-founder, Iktos
Quentin Perron is a medicinal chemist by training. He holds a PhD in organometallic chemistry from the University of Geneva. During his post-doc fellowship at UCLA he worked on the total synthesis of Brasillicardin A, a complex natural molecule known for having a potent immunosuppressive activity. After working as a medicinal chemist in CNS indications at Laboratoires Servier, he switched to data science and chemoinformatics at Quinten, a company specialized in data science services. In 2016, with his business partners Yann Gaston-Mathé and Nicolas Do Huu, he co-founded Iktos, a start-up company developing AI technologies for new drug design. He is now the CSO of the company.
Stefani Gamboa
Application Scientist, Iktos
Stefani Gamboa is a pharmaceutical and computational chemist by training. She holds a degree in Pharmaceutical Chemistry and a PhD in theoretical and bioinorganic chemistry, with a focus on quantum bioinorganic systems. Her doctoral research centered on the experimental design and theoretical modeling of polynuclear copper complexes, serving as bioinspired models for copper-containing enzymes with applications in catalysis and magnetic materials. Stefani gained industry experience at GlaxoSmithKline before moving into her current role as an Application Scientist at Iktos, where she works at the intersection of drug discovery, generative AI, and computational chemistry.
